BCL2 and acute myeloid leukemia: This LSC-specific signature has been recently associated with deep and durable responses observed in newly diagnosed AML treated with the selective inhibitor of BCL-2 venetoclax in combination with azacytidine, especially in IDH1/2-mutated patients [30].